CN111134295A - Preparation of high content synephrine extracts from immature citrus fruits, method and use thereof - Google Patents
Preparation of high content synephrine extracts from immature citrus fruits, method and use thereof Download PDFInfo
- Publication number
- CN111134295A CN111134295A CN201811465867.9A CN201811465867A CN111134295A CN 111134295 A CN111134295 A CN 111134295A CN 201811465867 A CN201811465867 A CN 201811465867A CN 111134295 A CN111134295 A CN 111134295A
- Authority
- CN
- China
- Prior art keywords
- synephrine
- fruit
- group
- extract
- fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 title claims abstract description 141
- 229960003684 oxedrine Drugs 0.000 title claims abstract description 70
- 239000000284 extract Substances 0.000 title claims abstract description 63
- 235000020971 citrus fruits Nutrition 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims description 38
- 238000002360 preparation method Methods 0.000 title abstract description 3
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims abstract description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 69
- 235000013399 edible fruits Nutrition 0.000 claims description 57
- 238000000605 extraction Methods 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 5
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 5
- 235000011869 dried fruits Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 230000010355 oscillation Effects 0.000 claims description 2
- 230000037221 weight management Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 abstract description 7
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 239000000047 product Substances 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 4
- 238000004260 weight control Methods 0.000 abstract description 4
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract description 3
- 229960002179 ephedrine Drugs 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 88
- 239000000341 volatile oil Substances 0.000 description 46
- 235000005979 Citrus limon Nutrition 0.000 description 41
- 244000131522 Citrus pyriformis Species 0.000 description 41
- 235000012000 cholesterol Nutrition 0.000 description 41
- 235000005911 diet Nutrition 0.000 description 34
- 230000037213 diet Effects 0.000 description 34
- 240000000560 Citrus x paradisi Species 0.000 description 32
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 21
- 235000009200 high fat diet Nutrition 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 20
- 108010007622 LDL Lipoproteins Proteins 0.000 description 18
- 102000007330 LDL Lipoproteins Human genes 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 244000276331 Citrus maxima Species 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 14
- 235000013305 food Nutrition 0.000 description 11
- 102000016267 Leptin Human genes 0.000 description 10
- 108010092277 Leptin Proteins 0.000 description 10
- 229940039781 leptin Drugs 0.000 description 10
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 10
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 10
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 235000011941 Tilia x europaea Nutrition 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000004571 lime Substances 0.000 description 7
- 125000003473 lipid group Chemical group 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000207199 Citrus Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- -1 caffeine Chemical compound 0.000 description 5
- 230000005089 fruit drop Effects 0.000 description 5
- 210000001596 intra-abdominal fat Anatomy 0.000 description 5
- 229940087305 limonene Drugs 0.000 description 5
- 235000001510 limonene Nutrition 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 235000001759 Citrus maxima Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 4
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000005070 ripening Effects 0.000 description 4
- 238000002137 ultrasound extraction Methods 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 3
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 235000019625 fat content Nutrition 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 244000183685 Citrus aurantium Species 0.000 description 2
- 235000007716 Citrus aurantium Nutrition 0.000 description 2
- 241000675108 Citrus tangerina Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZIKZPLSIAVHITA-UHFFFAOYSA-N Nomilinic acid Natural products CC(=O)OC(CC(O)=O)C1(C)C(C(C)(C)O)CC(=O)C(C23OC2C(=O)O2)(C)C1CCC3(C)C2C=1C=COC=1 ZIKZPLSIAVHITA-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 210000000702 aorta abdominal Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000001827 citrus limon l. burm. f. peel extract Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000010209 hesperetin Nutrition 0.000 description 2
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 2
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 2
- 229960001587 hesperetin Drugs 0.000 description 2
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940092251 lemon peel extract Drugs 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- KPDOJFFZKAUIOE-HPFWCIFASA-N nomilin Natural products O=C(O[C@H]1[C@@]2(C)[C@@H](C(C)(C)OC(=O)C1)CC(=O)[C@]1(C)[C@@H]2CC[C@@]2(C)[C@H](c3cocc3)OC(=O)[C@@H]3O[C@@]123)C KPDOJFFZKAUIOE-HPFWCIFASA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 235000017317 Fortunella Nutrition 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000002154 agricultural waste Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N anhydrous creatine Natural products NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical group C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000020866 grapefruit diet Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000010699 lard oil Substances 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000031142 liver development Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- KPDOJFFZKAUIOE-WNGDLQANSA-N nomilin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@H]2C(C)(C)OC(=O)C[C@@H]([C@]42C)OC(=O)C)C=COC=1 KPDOJFFZKAUIOE-WNGDLQANSA-N 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 230000010152 pollination Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 239000012716 precipitator Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
- A23L5/32—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation using phonon wave energy, e.g. sound or ultrasonic waves
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
- A23L5/34—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation using microwaves
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention relates to an extract containing high-content synephrine which is separated and purified from immature citrus fruits and a preparation method thereof. The high-content synephrine extract prepared by the invention can replace ephedrine and is applied to preparing supplements for weight control and blood fat reducing health care products by mixing with other compound materials.
Description
Technical Field
The invention relates to a method for extracting synephrine from citrus fruits. More particularly, the present invention relates to a method for separating and purifying high-content synephrine extracts from unripe citrus fruits or pericarps.
Background
In recent years, the living standard of people in China is improved, diet is influenced by western countries, the dietary habits are gradually changed into high oil, high sugar, high calorie and refined forms, however, the food indirectly causes overhigh concentration of Low Density Lipoprotein (LDL) or overlow concentration of High Density Lipoprotein (HDL) in blood, causes atherosclerosis and insulin resistance, easily causes blood sugar and blood lipid abnormality to increase oxidation pressure, has close correlation with peroxidation of free radicals and fat, and causes the increase of disease suffering rates of vascular diseases, second diabetes and the like, according to the statistics of health and welfare department of 105 years, the heart diseases, the cerebrovascular diseases and the diabetes of ten causes of death of people in China respectively occupy the second place, the fourth place and the fifth place, and are caused by interaction of multiple factors, but obesity is the most main cause of the diseases. Therefore, under the growing health consciousness and the popularization of preventive medicine concept, the utilization of natural antioxidants and medicinal plants is increasingly gaining attention.
In the supplement field, 75% of products are supplements formed by mixing synephrine and other stimulants (such as caffeine, green tea and cocoa). the synephrine has the effects of boosting pressure, resisting shock, improving metabolism and improving basic metabolism, is most representative of weight reduction in recent research and can promote sympathetic nerve activity, increase thermogenesis and stimulate lipolysis to achieve fat oxidation, and the mechanism is presumed that the synephrine can act on β 1-, β 2-, β 3-and α -adrenoreceptors to rapidly oxidize fat.
Citrus fruits are one of the international large fruit crops, and the annual yield in taiwan is about 47 ten thousand tons, and the pericarp, fallen fruit or thinned fruit of citrus fruits contain many active substances, such as synephrine, essential oil, phytosterol, limonin, phenolic acid, flavonoid and the like. In recent years, the chemical structure of synephrine has been proved to be similar to that of ephedrine, both of which have the effect of reducing weight, however, ephedrine has limited weight-reducing effect and has excessive side effects (such as causing anxiety, hypertension and the like), and is prohibited from being used in dietary supplements by the U.S. FDA in 2004.
It is known that the fruit of lime (Citrus aurantium l., also known as bitter orange) contains the major active ingredient synephrine, and that extracts thereof have been widely used for appetite suppression and dietary supplements, while lime fruit is used in various juices and foods. Many studies have shown that lime fruit extracts are safe health Food additives (M.D. arbor et al, Food and pharmaceutical nomenclature.46, 2770-2775,2008; Marcelo Dutra arbor et al, Regulatory nomenclature and pharmacy.54, 114-117,2009; N.S. Deshmukh et al, nomenclature reports.4,598-613,2017).
The pericarp, fruit drop and fruit thinning of citrus fruit are usually discarded as waste or disposed of as fertilizer, with few other uses. The citrus fruits have two situations of physiological fruit drop in the young fruit period, and the first situation is that pollination is incomplete, so that embryonic plants are developed or malnutrition is caused; the second is caused by endogenous hormones in the early-maturing embryo strains. In addition, if the amount of fruit bearing is too large, farmers may reduce the excessive load on the plants by thinning and appropriately picking off the late-flowering fruits. However, the number of immature fruits in fruit drop and thinning is quite large, and only a small amount of immature fruits are used in traditional medicine, and most of immature fruits are burned as fertilizer or agricultural waste.
Disclosure of Invention
In view of the above, the main object of the present invention is to provide a method for preparing synephrine extract with high content from unripe fruit part of citrus fruit.
Accordingly, one aspect of the present invention is directed to a method for preparing a synephrine-rich extract from unripe citrus fruit parts, said method comprising:
taking dried immature citrus fruit or pericarp thereof;
extracting with ultrasonic wave, stirring or microwave method and methanol as solvent, wherein the ratio of the weight of dried fruit or pericarp to the volume of methanol is 1:8-1:10 g/ml;
repeating the extraction step for 2 times for the residue after centrifugation and filtration;
combining the extract liquor; and
the combined extracts are concentrated to remove the solvent to obtain an synephrine-rich extract.
In some embodiments of the invention, the immature citrus fruit comprises young fruit, fallen fruit and thinning fruit.
In one embodiment of the invention, the immature citrus fruit part is the exocarp of a citrus fruit in the young fruit stage.
In another embodiment of the present invention, the dried unripe citrus fruit or pericarp is ground prior to extraction.
In another embodiment of the invention, the methanol is added in an amount of 5-10 ml/g dry weight of the fruit.
In other embodiments of the present invention, the ultrasonic method is performed by ultrasonic oscillation at 4-25 ℃ for 20 minutes-2 hours.
In other embodiments of the invention, the stirring is carried out at an extraction temperature of 25-28 ℃ for 20 minutes to 2 hours.
In other embodiments of the present invention, the microwave process is an extraction in a closed microwave-assisted extraction system at an elevated temperature of 30 ℃ to 64 ℃ for 10-15 minutes.
In other embodiments of the invention, the ratio of the weight of the dried fruit or peel to the volume of methanol is 1:8 g/ml.
Another aspect of the invention relates to a high content synephrine extract prepared according to the method of the invention.
In some embodiments of the invention, the high content of synephrine extract is from the exocarp of citrus fruit during the young fruit stage.
In some embodiments of the invention, the immature citrus fruit part is the epicarp of the young fruit.
In another aspect, the present invention relates to a composition for weight management comprising a high content of synephrine extract prepared according to the method of the present invention.
In another aspect, the present invention relates to a composition for reducing blood lipid, comprising the high content of synephrine extract prepared by the method of the present invention.
The method for preparing the high-content synephrine extract from the immature citrus fruit part effectively extracts the synephrine in the immature citrus fruit by using the immature citrus fruit peel, the fruit drop and the fruit thinning fruit as raw materials, and further uses the high-content synephrine extract for researching and developing health-care food or compound food, so that the purpose of reducing environmental pollution caused by wastes can be achieved, and the economic value of the immature citrus fruit peel, the fruit drop and the fruit thinning fruit can be increased. In addition, the content of synephrine in citrus fruit varies with the ripening months and is inversely proportional to the ripeness of the citrus fruit and the fruit diameter.
Drawings
Fig. 1 shows the yield of seedless lemon pericarp extracted by ultrasonication and various solvents (methanol (100% (v/v)), ethanol (95% (v/v)) and water), the yield (%) being the extract weight after concentration/pericarp weight 100%.
Fig. 2 shows the yields obtained by extracting seedless lemon peels with stirring and with different solvents (methanol (100% (v/v)), ethanol (95% (v/v)) and water), yield (%) 100% of the concentrated extract weight/peel weight.
Fig. 3 shows the yields obtained by extracting seedless lemon peels using a microwave method and various solvents (methanol (100% (v/v)), ethanol (95% (v/v)) and water), the yield (%) being the extract weight after concentration/peel weight 100%.
FIG. 4 is an HPLC chromatogram of a synephrine standard and a shaddock peel concentrated extract, wherein a represents the synephrine standard, and b and c are HPLC chromatograms of shaddock peel concentrated extracts of different batches.
FIG. 5 shows the content of synephrine in concentrated extracts obtained from seedless lemon pericarp at the young fruit stage, the strong fruit stage and the mature stage using ultrasonic method, stirring method, microwave method and methanol solvent.
Detailed Description
For a better understanding and appreciation of the objects, features, and advantages of the invention, reference should be made to the following detailed description taken in conjunction with the accompanying drawings.
The "citrus fruit" referred to in the specification includes species such as orange, tangerine, grapefruit, kumquat, lemon, and the like.
The fruit of the plant has a protective function for the seeds and can help the seeds to spread after the seeds are mature. The exocarp of citrus fruit consists of an outer epidermal layer, oil glands and parenchyma cells containing crystals; the mesocarp contains a large number of parenchyma cells, vascular tissues among the parenchyma cells are in a net distribution, and the tangerine pith is obtained after the fruit is mature. Under normal climatic conditions, the ripening process and progress of the fruit can be indicated by changes in the color of the peel. For example, the late maturing varieties in most sweet oranges, wide-skinned oranges, turn green and yellow to 2/3, which is considered to have reached eighty percent maturity. As used herein, the term "immature citrus fruit" refers to fruit that has not reached maturity criteria, preferably citrus fruit at the young fruit stage.
EXAMPLE one, different extraction methods and solvents for preparing high content sinephrine extracts
In this embodiment, the seedless lemon pericarp is extracted by using ultrasonic waves, stirring, microwaves and different solvents (methanol, ethanol and water) to obtain an extract, and the obtained yield (percent) is calculated as the weight of the concentrated extract per pericarp and 100 percent), so that how much extract can be extracted from 100g of pericarp can be known, and the content of synephrine in the extract can be further analyzed and converted to establish the condition for extracting the synephrine by using the optimal solvent.
An ultrasonic extraction method (Shiming Li et al, 2006, Journal of agricultural and food chemistry.54(12),4176-4185) was performed by adding 8mL of methanol (100% (v/v)), ethanol (95% (v/v)) and an aqueous solution to 1g of dried seedless lemon powder, oscillating the mixture for 20 minutes to 2 hours (extraction temperature: 28 ℃) with ultrasonic waves, centrifuging the mixture, adding the residue to the solvent for extraction, filtering the mixture with NO.1 filter paper, combining the two filtrates in a concentration bottle, concentrating the mixture at 40 ℃ under reduced pressure, quantifying the mixture to 10mL, and filtering the mixture with 0.22 μm filter membrane to 1 mL.
The stirring extraction method comprises adding 1g dried Seedless lemon powder into 8mL methanol (100%), ethanol (95%) and water solution respectively, stirring with a stirrer for 20 min-2 hr (extraction temperature: 28 deg.C), centrifuging, adding the above solvent into the residue, extracting, filtering with NO.1 filter paper, mixing the two filtrates, concentrating at 40 deg.C under reduced pressure to give 10mL, filtering with 0.22 μm filter membrane to give 1 mL.
Referring to Inoue et al, 2010, Food Chemistry,123: 542-; the ethanol solvent condition was 30 ℃ raised to 78 ℃ (15 minutes) and maintained for 30 minutes; raising the temperature of the methanol solvent to 64 ℃ (12 minutes) under the condition of 30 ℃, maintaining the temperature for 30 minutes, centrifuging, adding the residue into the solvent for extraction, filtering by using NO.1 filter paper, combining the two filtrates into a concentration bottle, controlling the temperature to be 40 ℃, carrying out reduced pressure concentration, quantifying to 10mL, and filtering 1mL by using a 0.22 mu m filter membrane. As shown in fig. 1, 2 and 3, the extraction using methanol as the solvent can achieve significantly higher extraction rates in the ultrasonic method, the stirring method and the microwave method than those using ethanol and water as the extraction solvent.
Therefore, as a preferred embodiment of the present invention, immature citrus fruits are dried (drying conditions: drying with a 50 ℃ hot air dryer to a moisture content of 10% or less) and then subjected to ultrasonic, agitation or microwave extraction with methanol (the ratio of the weight of the fruits to the volume of methanol is about 1:8 g/ml). The extraction mixture was then centrifuged at 3000rpm for 15 minutes and filtered. The methanol ultrasonic extraction step was repeated 2 more times on the obtained residue. The extracts obtained in the respective steps are combined and concentrated (concentration condition: concentration is carried out by a concentration drier at 60 ℃ until no solvent exists), and the solvent is removed to obtain a concentrated extract. (see Li et al (2006) for extraction of synephrine, phenolic compounds, and flavonoids).
Example II analysis of the extracts for the content of synephrine
In this example, the content of synephrine in the concentrated extract was measured by HPLC analysis. Firstly, the synephrine standard substance with different concentrations is analyzed by HPLC, and a standard curve is drawn according to the concentration and the area so as to calculate the content of the synephrine in the sample. The conditions of the HPLC apparatus and the chromatographic column for analysis were as follows: the instrument specification is as follows: HITACHI Pump L-2130; a detector: HITACHI UV Detector L-2400; analysis software: HITACHI Model D-2000 EliteChromograph Data Station Software; separating the tubular column: RP-18GP250 (250X 4.6mm, Mightysil, Kanto Chem Co., Inc.); mobile phase: a.10% (v/v) methanol solution with addition of 0.05% (v/v) formic acid, B.100% (v/v) methanol solution with addition of 0.05% (v/v) formic acid; setting the flow rate: 1.0 mL/min; sample injection amount: 10 mu L of the solution; UV light wavelength: 280 nm; mobile phase gradient:
time (min) | A(%) | B(%) |
0 | 100 | 0 |
5 | 80 | 20 |
35 | 45 | 55 |
70 | 35 | 65 |
75 | 35 | 65 |
80 | 0 | 100 |
85 | 0 | 100 |
90 | 100 | 0 |
95 | 100 | 0 |
The HPLC analysis of the synephrine standard and the peel of pomelo is shown in FIG. 4. The results show that the comparison of the synephrine standard and the peel of the pomelo proves that the peel of the pomelo also contains the synephrine compound, and the time position of the synephrine in the peel of the pomelo can be confirmed so as to facilitate the subsequent collection and purification of the solution of the synephrine.
Example III analysis of the content of Indenofurin in Citrus fruits at young fruit stage, strong fruit stage and mature stage
Concentrated extracts were prepared from pomelo, orange, ponkan and seedless lemon fruits at the young, strong and mature fruit stages, respectively, by the methanol ultrasonic extraction method described in example one, and analyzed and calculated for the content of synephrine by HPLC. See table 1 below for results.
TABLE 1 variation of the content of sinephrine in young fruit, strong fruit and mature fruit of four citrus fruits
1The values in the table are all expressed as mean. + -. SD, significant differences (p) between the values<0.05, n ═ 3) series were analyzed using Duncan's range test
2The unit is fresh citrus fruit weight
3The unit is mg/100 g dry weight of pericarp
As shown in Table 1, the content of synephrine in pomelo, orange, ponkan and seedless lemon in the young fruit stage is significantly higher than that in the strong fruit stage and the mature stage. The cells of the tissues of various parts inside the young fruit are undergoing vigorous cell division, wherein the pericarp thickening speed is the fastest. In the fruits in the strong fruit period and the mature period, the juice cells grow and are shaped, the juice is rapidly increased, the weight of the fruits is obviously increased, the color of the fruits begins to change due to the decomposition of chlorophyll, the accumulation of carotenoid, anthocyanin and exocarpium citri rubrum, and the aroma is also improved along with the increase of the maturity. Therefore, the content of synephrine in citrus fruits varies according to the ripening months, and shows that the content is inversely proportional to the fruit diameter, so that if a higher content of synephrine extract is desired, it is necessary to use young fruits with low ripening as raw materials.
Example four Effect of different extraction methods on the content of Indomalin in Seedless lemon pericarp
Using the ultrasonic, stirring and microwave extraction method described in example one and methanol as an extraction solvent, concentrated extracts were prepared from seedless lemon pericarp in the young fruit stage, the strong fruit stage and the mature stage, respectively, and the content of synephrine in the extract was analyzed and calculated by using HPLC described in example two. The results are shown in FIG. 5, which shows that the concentration of sinephrine in the concentrated extract obtained by stirring extraction is higher than that obtained by microwave extraction and ultrasonic extraction.
Example five evaluation of weight control and hypolipidemic efficacy of high content synephrine extracts
This example was conducted to test the effect on weight gain and hyperlipidemia induced by high fat diet in rats by obtaining synephrine-rich extracts and essential oils from the peel of pomelo, seedless lemon during the young fruit stage according to the procedure described in example one.
Source, feeding, dosing and sampling of experimental animals (high-fat diet mice)
Male Wistar rats of 6 weeks of age of leszidae biosciences were used as test animals for weight, blood lipid, and body lipid regulation, and 76 Wistar rats were purchased. The weights were grouped on the first day of purchase, assigned to mean standard deviation of each group (p <0.05), and after 1 week of acclimation, they were grouped according to weight at week 2, with 8 groups in total, except for 12 control groups, and 9 groups. Rats were housed in stainless steel cages with the animal house temperature set at 22 + -2 deg.C and relative humidity at 40-60%, with automatic timer control of light time, light time (light period) 8:00 in the morning to 8:00 in the evening, dark time (dark period) 8:00 in the evening to 8:00 in the morning, and feed and drinking water were taken from the house. During the experiment, food intake and water intake were recorded daily, body weight was measured 2 times per week, blood was collected in the eye socket 1 time per 2 weeks, plasma was centrifuged at 4 ℃ (1500rpm) for 20min, serum was taken out to determine changes in TG, TC, HDL and LDL, and sacrificed after 12 weeks of rearing, while feces were collected for 3 days in each group on average before sacrifice, rats were fasted for 12h before sacrifice, and coma and sacrifice were performed with isoflurane. Before sacrifice, the blood of the eye fossa is collected and weighed, and then the blood of the abdominal aorta, visceral organs (including kidney and liver) and visceral adipose tissues (including perirenal fat and accessory testis fat) are collected during sacrifice. Blood is centrifuged for 20min at 4 ℃ (1500rpm) (KUBOTA-374), serum is collected, the serum in the orbital part is used for detecting the content of TG, TC, HDL and LDL, the serum in the abdominal aorta is sent to Dahua medical examination center in Zhanghuaxian county of China for detecting insulin (insulin) and thin voxel (leptin), after the liver and visceral fat of each group are cleaned by PBS, part of the liver is rapidly frozen by liquid nitrogen and stored in a refrigerator at-80 ℃ for the content measurement of TG and TC in the liver, and the rest is put into 10% formalin solution for subsequent examination.
Preparing high-fat diet feed:
the Control group (C: Control group) was fed with AIN-76 formula (AIN,1977) feed; the High fat High cholesterol diet (HF: High fat) was fed with a feed based on the AIN-76 formula plus 10 wt% lard, 5 wt% corn oil and 0.2 wt% cholesterol; positive control (Positive control) was fed a feed based on AIN-76 formulation plus an additional 10% lard, 5% corn oil, 0.2% cholesterol and p-synephrine (15mg/kg/B.W.) dosage referenced to arbor et al (M.D. arbor et al, Food and Chemical society.46, 2770-2775,2008); the experimental group of pomelo is based on AIN-76 formula, 10 wt% of lard oil, 5 wt% of corn oil and 0.2 wt% of cholesterol are added, then pomelo non-essential oil peel powder and essential oil are added respectively, the experimental group (excluding positive control group) is divided into low dose and high dose groups, and the prepared feed is stored in a refrigerated cabinet at 4-6 ℃ for standby after 12 weeks.
Determination of triglycerides:
this experiment determined that triglycerides in serum were analyzed with Randox kit (cat. No. tr213). And (3) putting 2 mu L of each group of serum samples into a 96-hole plate, adding 200 mu L of triglyceride buffer in the dark, uniformly mixing, standing for 10min at room temperature, measuring the light absorption value of the sample with the wavelength of 500nm by using an ELASA reader, and converting the concentration of the triglyceride in the sample by referring to a product providing formula. The reference formula is as follows:
triglyceride (mg/dL) ═ A (sample abs/A standard abs). Standard conc (148.6)
Determination of cholesterol:
the total cholesterol in serum determined in this experiment was analyzed using Randox kit (cat. No. ch201). And (3) putting 2 mu L of each group of serum samples into a 96-hole plate, adding 200 mu L of cholesterol reagent in the dark, uniformly mixing, standing for 10min at room temperature, measuring the light absorption value of the sample with the wavelength of 500nm by using an ELASA reader, and converting the concentration of the cholesterol in the sample by referring to a product providing formula. The reference formula is as follows:
cholesterol (mg/dL) ═ A sample abs/A standard abs standard conc (110.6)
Determination of low density lipoprotein:
this experiment determines low density lipoprotein cholesterol in serum which is analyzed using Randox kit (Cat. No. KGLCH103). Taking 50 mu L of each group of serum samples, adding 500 mu L of LDL precipitator, uniformly mixing, standing for 10min at room temperature, centrifuging by a low-temperature centrifuge (1500 rpm; 15min), taking 12.5 mu L of supernatant, adding 250 mu L of cholesterol reagent, uniformly mixing, standing for 10min at room temperature, measuring the light absorption value of the sample with the wavelength of 500nm by using an ELASA reader, and converting the concentration of the low-density lipoprotein cholesterol of the sample by referring to a product providing formula. The reference formula is as follows:
LDL (mg/dL) ═ (A sample abs/A standard abs). Standard conc (316.25)
Determination of insulin and leptin:
the Dahua medical examination institute in Zhanghua county was entrusted with inspection.
Animal formula: animal feed formulations refer to Feng et al (Li-Jun Feng et al, Food research International 44,404-409,2011 for details) and AIN-76 formulations (see Lien EL1, et al, Food Chem Toxicol 39(4):385- "392, 2001). The following animal formula tables are provided, and the synephrine in the peel extract of the pomelo and the seedless lemon is used as the drug administration target, and the non-toxic dose of the synephrine is recorded in the literature, and the addition of the peel extract and the essential oil of the two citrus fruits is converted into the required content of the high-fat diet formula. The detailed formulation is shown in tables 2 and 3.
In table 3 below, C: a control group given a normal diet; HF: a group of high fat diets given a high oil and high cholesterol diet; synephrine: the treatment group was given a high oil and high cholesterol diet containing 0.015% synephrine; GPF-L: the treatment group was given a high oil and high cholesterol diet containing 6.8% of grapefruit peel extract; GPF-H: the treatment group was given a high oil and high cholesterol diet containing 20.4% of grapefruit peel extract; GPEO-L: administering a low dose treatment group containing a high oil and high cholesterol diet containing 0.04% grapefruit essential oil; GPEO-H: the high dose treatment group was given a high oil and high cholesterol diet containing 0.16% grapefruit essential oil.
TABLE 3 Wen Dan shaddock-animal feed formulation (unit: weight percent)
In table 4 below, C: a control group given a normal diet; HF: a group of high fat diets given a high oil and high cholesterol diet; synephrine: a treatment group given a high oil and high cholesterol diet containing 0.00625 wt% synephrine; LEON: the treatment group was given a high oil and high cholesterol diet containing 0.744 wt% of seedless lemon essential oil; LEOH: the treatment group was given a high oil and high cholesterol diet containing 2.232 wt% seedless lemon essential oil; LPN: the treatment group was given a high oil and high cholesterol diet containing 24.2 wt% of seedless lemon peel extract; LPH: the treatment group was given a high oil and high cholesterol diet containing 72.6 wt% of seedless lemon peel extract.
TABLE 4 Seedless lemon-animal feed formulation (unit: weight percent)
As a result:
A. weight effect of high content of synephrine extract (Peels) and Essential Oil (EO) on high fat diet rats of pericarp of Pomelo (Pomelo) and seedless lemon (Lime)
The results show that the initial average body weight of each group of rats fed with pomelo and lemon diets has no statistical difference after statistical analysis, and after 12 weeks of high-fat high-cholesterol experiment, the final body weight of each group measured before sacrifice can find that the average body weight of the high-fat group of the pomelo and lemon diet experiment is increased by 440.8 +/-0.08 g and 361.3 +/-5.33 g respectively, which are obviously higher than that of the control group, the positive control group, the pericarp group and the essential oil group. Wherein the weight of the Xinnevirin group of the pomelo diet is reduced by 93.6g compared with the high-fat group; the weight of the low-dose and high-dose pericarp groups was reduced by 114.8g and 113.9g, respectively; the body weight of the low dose and the high dose of the essential oil group was reduced by 93g and 119.2g, respectively. Compared with the high-fat group, the weight of the synephrine group with the lemon diet is reduced by 32 g; the weight of the low dose and high dose peel groups was reduced by 305.8g and 467.5g, respectively; the body weight of the low dose and the high dose of the essential oil group was reduced by 71.9g and 171.9g, respectively.
The main compound of the essential oil, namely the Limonene, can regulate the expression of uncoupling protein-2 (UCP-2) and sterol-regulatory element binding protein (SREBP-1), wherein the uncoupling protein-2 and the sterol-regulatory element binding protein (SREBP-1) are important factors for fatty acid oxidation and triglyceride synthesis respectively, and the Limonene (Limonene) induces the essential oil to improve fat metabolism. In addition, limonene can improve the circulatory system, discharge carbon dioxide and water, and allow the lymphatic system to circulate and normally discharge waste. The synephrine, dietary fiber and flavonoid in the peel have relevant influence on weight control, wherein the synephrine can stimulate adrenaline to influence the action of cardiovascular system, the action can generate heat in human body to help reduce body fat, and the active ingredients in the citrus peel and essential oil thereof can effectively reduce the increase of weight.
B. Effect of high content of synephrine extracts (Peels) and Essential Oil (EO) on Triglyceride (TG) content in high fat diet rat of pericarp of Pomelo (Pomelo) and seedless lemon (Lime)
The results show that the initial mean triglyceride of each group of rats fed with pomelo and lemon diets was statistically different after statistical analysis, while the triglyceride content of the serum of the high-fat group was 173.73mg/dL and 114.53mg/dL in the high-fat group at weeks 6 and 4 respectively in the high-fat diets of pomelo and lemon, which indicates that the induction of the triglyceride content in the high-fat group was successful. After a 12-week feeding of pomelo and lemon diets, the high dose group of essential oils was found to be the best, probably the most essential compound limonene, which prevented the development of dyslipidemia in mice (sting et al, 2013). The pomelo and lemon peel groups are optimized at low dose, the possible reason for effectively reducing serum triglyceride is the nomilin compound, the feeding of 0.2% (w/w) nomilin can find that the body weight, serum glucose and insulin of mice with high fat diet are obviously reduced and the glucose tolerance is improved, and the active ingredients in the citrus peel and essential oil thereof can effectively reduce the increase of serum triglyceride.
C. Effect of high content of synephrine extracts (Peels) and Essential Oil (EO) on total cholesterol levels in high fat diet rats by pericarp of Pomelo (Pomelo) and seedless lemon (Lime)
The data in the above table show that the initial average total cholesterol of all groups of rats fed with pomelo and lemon diets was not statistically different after statistical analysis, while the triglyceride content in the serum of the high-fat group was 75.53mg/dL and 69.45mg/dL highest at weeks 6 and 4 respectively in the high-fat diets of pomelo and lemon, indicating that the total cholesterol content in the high-fat group was successfully induced in the experiment. After 12 weeks of feeding the diets of pomelo and lemon, the synephrine group, pericarp group and essential oil group were found to be effective in inhibiting cholesterol production. It has been suggested in the literature that an increase in the number of low density lipoprotein receptors resulting from inhibition of HMG-CoA reductase and ACAT activity is effective in inhibiting cholesterol production and reducing serum low density lipoprotein concentration (Nicolosi et al, 1997). In conclusion, the active ingredients in the citrus peel and essential oil thereof can effectively reduce the increase of total cholesterol in serum.
D. Effect of high content of synephrine extracts (Peels) and Essential Oil (EO) on the low density lipoprotein content of rats with high fat diet of peel of Pomelo (Pomelo) and seedless lemon (Lime)
The data in the table above shows that there was no statistical difference in the initial mean low density lipoprotein for each group when rats were given a grapefruit and lemon diet. The low-density lipoproteins contained a large amount of cholesterol, and the low-density lipoproteins in the serum of the high-fat diet groups of the pomelo and lemon experiments were 34.14mg/dL and 39.2mg/dL at week 6 and 4, respectively, which were highest, so that the low-density lipoproteins in the high-fat group of the experiment were higher than those in the other groups. The results show that both the pericarp group and the essential oil group are effective in reducing the low density lipoprotein content. The literature indicates that the citrus flavonoid and the compound with strong oxidation resistance form the formula food, can effectively reduce the content of 40 percent of low-density lipoprotein, and simultaneously inhibit cholesterol from forming fatty liver in the liver. Wherein the hypermethoxyflavonoids in the pericarp can reduce the serum very low density lipoprotein and low density lipoprotein of high fat diet hamster (Kurowska et al, 2004; Liet al, 2006).
E. Effect of high content of synephrine extract (Peels) and Essential Oil (EO) on triglyceride and total cholesterol content in liver of high fat diet rat
It was found that administration of a diet containing more than 0% cholesterol resulted in a positive correlation between liver and plasma cholesterol levels and the levels of additive, and a reduction in β -oxidation-related creatine transferase I activity, and a retardation in fatty acid metabolism, leading to a sustained triglyceride production, which was delivered to the liver from very low-density lipoproteins, whereas the very low-density lipoproteins were not increased, resulting in a significant accumulation of triglycerides in the liver to form fatty liver (Fungwe et al, 1992; Liuet al, 1995). the data in the above table show that the total cholesterol and triglyceride levels in the liver of the high-lipid group of the grapefruit and lemon diet experiment were as high as 70mmol/L or higher, which is significantly different from those in the normal diet control group of 48.89-58.36, 46.9556.95mmol/L (p <0.05), which tends to cause the accumulation of fat in the hepatocytes, leading to fatty liver development, and that the total cholesterol level in the high-lipid group of grapefruit and the low-lipid group of the grapefruit diet was found to be lower than those in the high-cholesterol group, the low-cholesterol level of 48.59, 35% and 35.35% of the low-lipid group, and the low-lipid group was found to be lower than that the diet group of the low-lipid group, respectively, and the low-lipid group was found to be lower than that the diet.
When triglyceride is compared with high oil and fat in experimental group of shaddock, the low dose and high dose of pericarp group are respectively reduced by 6.58% and 29.18%; the low dose and the high dose of the essential oil are respectively reduced by 19.19 percent and 26.63 percent. When triglyceride is compared with high oil and fat in the experiment group of lemon diet, the low dose and the high dose of the pericarp group are respectively reduced by 36.26 percent and 40.84 percent; the low dose and the high dose of the essential oil group are respectively reduced by 23.14 percent and 27.64 percent. Among them, the two citrus fruits are most remarkable in reducing total cholesterol and triglyceride in liver at high dose of pericarp group, probably due to naringin, quercetin, hesperetin or polyphenol compound, and it is indicated in literature that hesperetin limits the increase of triglyceride and cholesterol in liver by the induction of orotic acid (Cha et al, 2001) or citrus chazukii polyphenol can activate cAMP-regulated kinase (AMKP) to activate liposome autophagy (lipoliver), preventing non-alcoholic fatty liver.
F. Effect of high content of synephrine extracts (Peels) and Essential Oil (EO) on fecal sterol content in high fat diet rats by pericarp of Pomelo (Pomelo) and seedless lemon (Lime)
Cholesterol is obtained by two routes, one is synthesized by the human body and the other is obtained from the diet, and the excretion mode also comprises two modes, namely cholesterol 7 α -hydrolase in the liver is excreted out of the body in the cholic acid mode after a series of reactions, and the excretion mode comprises cholesterol or plant sterol which is not absorbed or is excreted with bile, through stimulating cholesterol 7 α -hydrolase to increase acid cholesterol and neutral sterol in the excrement (Quintao et al, 1987). the data in the above table shows that the neutral sterol content in the excrement is 7.15mg/g in the high lipid group of the shaddock diet experiment, while the low and high dosages of the pericarp group are 8.38 and 14.06mg/g respectively, the low and high dosages of the essential oil group are 8.87 and 10.98mg/g respectively, the high lipid group of the lemon diet experiment is 7.56mg/g, while the low and high dosages of the pericarp are 7.61 and 11.56mg/g respectively, the low dosages of the essential oil group are 8.84 mg/g respectively, the lipid group of the lemon diet experiment is 7.56mg/g, the lipid group can prevent the bile acid from being absorbed in the intestinal tract, and the bile fiber can be absorbed by the intestinal tract, and the intestinal tract can be prevented from being accumulated in the intestinal tract, and the bile fiber can be effectively absorbed by the cholesterol absorption of the cholesterol.
G. Effect of high content of synephrine extracts (Peels) and Essential Oil (EO) on insulin and leptin content in high fat diet rats
Leptin is 167 amino acid peptides secreted by white adipose tissue, which modulates leptin effects via leptin receptors in the hypothalamus, while hyperphagia increases leptin content and conversely decreases leptin concentration, resulting in a concentration proportional to body fat. When leptin levels are reduced in vivo, central nerves and surrounding tissues are stimulated to signal increased appetite and reduced energy expenditure, conversely, when leptin levels are high, appetite is reduced. The results in the table show that the high fat group without pomelo and lemon diets contained 4.14 ng/mL and 8.28ng/mL, respectively, were the highest, and were significantly different from the pericarp and essential oil groups (p <0.05), indicating that high fat is likely to cause leptin resistance and fail to send signals to the central nervous system to increase energy consumption. The pericarp group and the essential oil group can effectively reduce the weight gain, so the lean body mass is lower than that of the high fat group.
Insulin is a hormone secreted by β cells of the pancreas, and stimulates organs in the body to store excess glucose and inhibit lipolysis of adipose tissue, but lipid accumulation in the abdomen is considered to be the main cause of systemic insulin resistance if it causes specific disappearance of insulin signaling pathway and impaired insulin regulation of glucose (Carey et al, 1996). the results listed in the above table indicate that 1.08 and 2.78ng/mL of high lipid group, which may have insulin resistance, are likely to have too high triglyceride and low density lipoprotein content in serum of high lipid group, and likely to have too much insulin secretion, resulting in abnormal blood fat metabolism (Chen et al, 2006). compared to the high lipid group, the pericarp group and essential oil group are significantly decreased (p <0.05), because insulin, in addition to metabolizing glucose, also affects fat metabolism, increases fat synthesis by liver and liver cells, decreases fat and triglyceride decomposition in muscle, and the experimental results indicate that the content of triglyceride in pericarp and essential oil group is lower than that normal glucose tolerance of insulin is achieved (Leey et al).
H. Effect of high content of synephrine extract (Peels) and Essential Oil (EO) on body fat content of rats with high fat diet from pericarp of Pomelo (Pomelo) and lemon (Lime)
Body fat includes essential fat and storage fat, while visceral fat is a storage fat that protects the viscera from damage, but is also prone to chronic disease. The experimental data in the table above show that in the high-fat group of the pomelo and lemon diet experiments, the visceral and testicular fat contents are 34.38g and 22.81g respectively; 32.52g and 20.44g were the highest because accumulation of adipose tissue correlated with the amount of triglyceride, which accumulated in visceral fat cells, increased the size of the cells and developed visceral fat obesity. Compared with the high-fat group, the low dose and the high dose of the peel group of the pomelo are respectively reduced by 9.67 percent and 19.18 percent, and the low dose and the high dose of the essential oil group are respectively reduced by 8.88 percent and 20.48 percent; the low dose and the high dose of the lemon peel group are respectively reduced by 73.27 and 100 percent, and the low dose and the high dose of the essential oil group are respectively reduced by 33.87 and 53.88 percent.
In summary, compared with untreated rats with high-fat diet, the immature citrus fruit peel extract of the present invention can effectively control the body weight and reduce the blood fat content of rats with high-fat diet, including triglyceride, total cholesterol and low-density lipoprotein content, and the efficacy of the extract can reach the same or better degree than that of a single compound of synephrine. Therefore, the high-content synephrine extract prepared according to the invention can be used for preparing health care products for weight control and blood fat reduction as active supplements.
Other embodiments
All features disclosed in this specification may be combined in any combination. Any feature disclosed in this specification may be replaced by alternative features serving the same, equivalent or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.
From the foregoing description, one skilled in the art can readily ascertain the essential characteristics of the described embodiments, and without departing from the scope thereof, can make various changes and modifications to the embodiments to adapt to various citrus fruits and application conditions. Accordingly, other embodiments are within the scope of the invention.
Claims (12)
1. A process for preparing a synephrine-rich extract from unripe citrus fruit parts, said process comprising:
taking dried immature citrus fruit or pericarp thereof;
extracting with ultrasonic wave, stirring or microwave method and methanol as solvent, wherein the ratio of the weight of dried fruit or pericarp to the volume of methanol is 1:8-1:10 g/ml;
repeating the extraction step for 2 times for the residue after centrifugation and filtration;
combining the extract liquor; and
the combined extracts are concentrated to remove the solvent to obtain an synephrine-rich extract.
2. The method of claim 1, wherein the immature citrus fruit is young fruit, fallen fruit or thinning fruit.
3. The method as claimed in claim 1, wherein the dried unripe citrus fruit or pericarp is ground prior to extraction.
4. The method of claim 1, wherein the part of the unripe citrus fruit is the exocarp of a citrus fruit in the young fruit stage.
5. The method of claim 1, wherein the ratio of the weight of the dried fruit or peel to the volume of methanol is 1:8 g/ml.
6. The method according to claim 1, wherein the ultrasonic method is ultrasonic oscillation at 4-25 ℃ for 20 minutes-2 hours.
7. The method of claim 1, wherein the stirring is carried out at an extraction temperature of 25-28 ℃ for 20 minutes to 2 hours.
8. The method of claim 1, wherein the microwave method comprises performing the extraction in a closed microwave-assisted extraction system at an elevated temperature of 30 ℃ to 64 ℃ for 10-15 minutes.
9. An extract with high content of synephrine isolated from immature citrus fruit parts, prepared by the method according to claim 1.
10. The synephrine-rich extract of claim 9, wherein the unripe citrus fruit part is the exocarp of a young fruit.
11. A composition for weight management comprising the high content synephrine extract of claim 9.
12. A composition for lowering blood lipid levels, comprising the synephrine-rich extract of claim 9.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW107139200A TWI713924B (en) | 2018-11-05 | 2018-11-05 | EXTRACT WITH HIGH CONTENT OF ρ-SYNEPHRINE FROM CITRUS UNRIPE FRUIT, THE PREPARING METHOD AND THE USE THEREOF |
TW107139200 | 2018-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111134295A true CN111134295A (en) | 2020-05-12 |
Family
ID=70515990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811465867.9A Pending CN111134295A (en) | 2018-11-05 | 2018-12-03 | Preparation of high content synephrine extracts from immature citrus fruits, method and use thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111134295A (en) |
TW (1) | TWI713924B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112293718A (en) * | 2020-06-04 | 2021-02-02 | 苏州汉德瑞生物工程有限公司 | Citrus extract and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101402577A (en) * | 2008-10-23 | 2009-04-08 | 浙江工商大学 | Method for extracting and separating levorotation-synephrine from green tangerine orange peel |
CN102050855A (en) * | 2010-12-28 | 2011-05-11 | 陕西嘉禾植物化工有限责任公司 | Method for comprehensively extracting synephrine and hesperidine from immature bitter orange raw material |
CN103387501A (en) * | 2013-07-13 | 2013-11-13 | 湖南鑫利生物科技有限公司 | Method for preparing high-purity L-synephrine |
CN106632547A (en) * | 2016-12-14 | 2017-05-10 | 雅安太时生物科技股份有限公司 | Method for extracting naringin, synephrine and pectin from young shaddock fruits |
-
2018
- 2018-11-05 TW TW107139200A patent/TWI713924B/en active
- 2018-12-03 CN CN201811465867.9A patent/CN111134295A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101402577A (en) * | 2008-10-23 | 2009-04-08 | 浙江工商大学 | Method for extracting and separating levorotation-synephrine from green tangerine orange peel |
CN102050855A (en) * | 2010-12-28 | 2011-05-11 | 陕西嘉禾植物化工有限责任公司 | Method for comprehensively extracting synephrine and hesperidine from immature bitter orange raw material |
CN103387501A (en) * | 2013-07-13 | 2013-11-13 | 湖南鑫利生物科技有限公司 | Method for preparing high-purity L-synephrine |
CN106632547A (en) * | 2016-12-14 | 2017-05-10 | 雅安太时生物科技股份有限公司 | Method for extracting naringin, synephrine and pectin from young shaddock fruits |
Non-Patent Citations (4)
Title |
---|
余兰兰等: "《现代生化分离技术及应用研究》", 吉林大学出版社 * |
刘伟等: "不同柑橘品种及保健品中辛弗林含量的比较", 《湖南农业科学》 * |
张国友等: "柑橘中天然产物辛弗林的研究进展", 《中国食物与营养》 * |
黄世敬等: "《轻松降血脂》", 31 March 2015, 金盾出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112293718A (en) * | 2020-06-04 | 2021-02-02 | 苏州汉德瑞生物工程有限公司 | Citrus extract and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
TWI713924B (en) | 2020-12-21 |
TW202017582A (en) | 2020-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hadidi et al. | Optimisation and kinetic study of the ultrasonic-assisted extraction of total saponins from alfalfa (Medicago sativa) and its bioaccessibility using the response surface methodology | |
US9745279B2 (en) | Sirtuin activator | |
CN101203270B (en) | Substances having body mass redistribution properties | |
RU2466736C2 (en) | High-polyphenol extract of herbal raw material | |
BRPI0618232A2 (en) | processes for obtaining lignan extracts and compositions containing lignan extracts | |
US20150125558A1 (en) | Pleuropterus multiflorus extract and dipsacus asperoides extract for secreting insulin-like growth factor and promoting bone structure growth, and method for preparing same | |
CN101146458B (en) | A method for preparing extract for the prevention and treatment of hyperlipidemia and obesity from the extract of aster spathulifolius aerial part and composition containing the same | |
WO1999025197A1 (en) | Fenugreek compositions having reduced taste and odor and methods of use | |
KR101369060B1 (en) | Antiobesity composition containing component originating in the bark of tree belonging to the genus acacia | |
CN111134295A (en) | Preparation of high content synephrine extracts from immature citrus fruits, method and use thereof | |
KR101803899B1 (en) | Composition for Improving Atopic Skin Using an Extract of Fermented Green Tea | |
KR101440781B1 (en) | Composition for Improving Liver Function Using an Extract of Wheat Bran | |
RU2707300C2 (en) | Method of producing drug having thyrotropic and antioxidant activity | |
Widodo et al. | The Effect of High Temperature Roasted Coffea liberica on Physiological and Histological Structure of Mice’s Kidney | |
KR101291342B1 (en) | A pharmaceutical composition comprising lindera erythrocarpa extract, fractions thereof, or compounds isolated from thereform | |
RU2366445C1 (en) | Method for making hepatoprotector | |
KR101018404B1 (en) | Compositions for reducing cholesterol comprising extracts of Vaccinium oldhami Miquel leaf as an active ingredient | |
JP2009221158A (en) | Neutral fat-reducing agent and suppressor of body fat increase | |
KR101332531B1 (en) | Composition for preventing and/or treating itching containing component originating in the bark of tree belonging to the genus acacia | |
JP2004161644A (en) | Pancreatic lipase inhibitor and food product containing the inhibitor | |
Cornelia et al. | Healthy drinks made from okra and green tea extract for reducing blood cholesterol | |
KR100625469B1 (en) | Method of extracting frulic acid from sweet potato stem | |
KR20210063041A (en) | Multifunctional food complex composition for preventing or improving obesity comprising essentially Cirsium setidens and barley sprout extracts, and preparing method thereof | |
WO1999025370A1 (en) | Methods for reducing the intestinal absorption of a caloric of compound in diabetics | |
RU2356569C1 (en) | Hypoglycemic and immunomodulatory agent production procedure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200512 |